<DOC>
	<DOCNO>NCT02775656</DOCNO>
	<brief_summary>The purpose observational follow-up study collect data systematically pregnancy offspring woman become pregnant participate Certolizumab Pegol ( CZP ) study whose pregnancy otherwise report UCB due potential CZP exposure pregnancy .</brief_summary>
	<brief_title>UCB Cimzia Pregnancy Follow-up Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Pregnancy identify patient participate interventional noninterventional Certolizumab Pegol ( CZP ) study conduct UCB , development partner , regardless phase treatment arm ( ie , commercial investigational , placebo comparator treatment ) , whose pregnancy spontaneously report UCB due potential CZP exposure pregnancy Sufficient information classify pregnancy prospective retrospective available Full initial reporter ( ie , woman healthcare provider ( HCP ) ) contact information report allow followup ( name , address , telephone number/email address ) contact information least 1 applicable HCP initial contact woman Consent participate provide Pregnancies result infant 1 year age time inform consent eligible participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CimziaÂ®</keyword>
	<keyword>CZP</keyword>
	<keyword>Pregnancy Follow study</keyword>
	<keyword>Autoimmune disease</keyword>
	<keyword>Pregnancy outcome</keyword>
	<keyword>major congenital malformation</keyword>
	<keyword>birth outcome</keyword>
	<keyword>malformation</keyword>
	<keyword>birth defect</keyword>
</DOC>